The reported studies have proven the crucial role of NOTCH1 in lung cancer and NSCLC, and according to the clinical trials reports, 30% of primary human NSCLCs exhibited Notch signaling activation by either NOTCH1 overexpression or numb downregulation (Yuan et al., 2014; Westhoff et al., 2009). The gene discussed is NOTCH1; the disease is lung cancer.